EGFR and non-small cell lung carcinoma: Because the measurable CSF concentration for first‐ or second‐generation EFGR‐TKIs in CSF is much lower than that for osimertinib, the combination of first‐ or second‐generation EGFR‐TKIs and local therapy, such as stereotactic radiosurgery (SRS), whole‐brain radiotherapy (WBRT), or brain surgery, has previously been investigated as an aggressive therapy in selective EGFR‐mutant NSCLC patients with BMs.